Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
Novel automated method aids busulphan monitoring
July 30th, 2003
A novel automated method aids busulphan monitoring in stem cell graft recipients. Bu "is an alkylating agent used in preparative regimen before stem cell transplantation (SCT)," researchers in Sweden explained. "Bu has a narrow therapeutic window, and underdosing or overdosing may have a fatal outcome for the patient." "Therapeutic drug monitoring (TDM) combined with dose adjustment is currently used to optimize and individualize therapy with Bu," noted M. Abdel-Rehim and colleagues at AstraZeneca R&D in Sodertalje. "However, this approach is limited to centers with laboratory facilities. An automated and easy method for measurement of Bu plasma...
Source: Biotech Week (2003-07-30)
|
